PHOTOTHERAPY systems
Foot Phototherapy
DERMATOLOGICAL TOOLS
PHOTOTHERAPY SERVICES
Regular Lamp Replacement
Maintenance Contracts
Risk-Free NB Conversion
Replacement Lamps
PRESCRIBING PHOTOTHERAPY
Phototherapy vs Biologics
PUVA - UVA plus Psoralen
NB UVB vs PUVA vitiligo study
Blue Lights for Acne
Blue Light Studies Prove Value
Scalp Psoriasis Treatment 
Narrowband UVB phototherapy
Treatment Protocol References
PHYSICIAN DISCOUNTS
WORKING WITH INSURERS
Medicare Reimbursement
Insurer Coverage and Payouts
Letter of Medical Necessity
PHOTOTHERAPy in practice
Adding Phototherapy to Practice
Pediatric Dermatology
Psoriasis Patients Underserved
Phototherapy for Podiatry
Small Units for Small Patches
Patient HOME UNITS
Full Body Folding Unit  
Handheld Spot Treatment 
Home UVB Light Panels
Efficacy of Home Phototherapy
Cost of At-Home Phototherapy
NEWS
NYT: Psoriasis drugs hit ceiling
Biologics cost more than house
State of phototherapy training
Upcoming Trade Shows
National Biological
Hear From Our Customers
On-site Manufacturing Facility
Current Research and Links
About Us
NEED HELP?
Terms and Conditions
Site Map
Contact Us
800-338-5045
 

Become a fan on


PATIENTS     PHYSICIANS     THIRD PARTY PAYERS     HOME       

Randomized Double Blind Trial of Treatment of Vitiligo
     Efficacy of Psoralen-UVA Therapy vs Narrowband UVB Therapy

Randomized Double Blind Trial of Treatment of Vitiligo: Efficacy of Psoralen-UVA Therapy vs Narrowband UVB Therapy. Yones SS, Der D, Palmer RA, Garibaldinos TM, Hawk JLM. Arch Dermatol 2007; 143:578-84.                                           Read Full Article
OBJECTIVE: To compare the efficacy of oral psoralen- UV-A (PUVA) with that of narrowband- UV-B (NB-UVB) phototherapy in patients with nonsegmental vitiligo.
DESIGN: Double-blind randomized study.
SETTING: Phototherapy unit in a university hospital.
PATIENTS:
Fifty-six patients with nonsegmental vitiligo.
INTERVENTIONS: 
Twice-weekly therapy with PUVA or NB-UVB.
MAIN OUTCOME MEASURES:
The change in body surface area affected by vitiligo and the color match of repigmented skin compared with unaffected skin were assessed after 48 sessions of therapy, at the end of the therapy course, and 12 months after the end of therapy.
RESULTS: 
The results in the 25 patients each in the PUVA and NB-UVB groups who began therapy were analyzed.  The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB group (P=.03); we suspect this difference was because of differences in efficacy and adverse effects between the two modalities, such that patients in the NB-UVB group wanted a longer course of treatment. At the end of therapy, 16 (64%) of 25 patients in the NB-UVB group showed greater than 50% improvement in body surface area affected compared with 9 (36%) of 25 patients in the PUVA group. The color match of repigmented skin was excellent in all patients in the NB-UVB group but in only 11 (44%) of those in the PUVA group (P<.001). In patients who completed 48 sessions, the improvement in body surface area affected by vitiligo was greater with NB-UVB therapy than with PUVA therapy (P<.007). Twelve months after the cessation of therapy, the superiority of NB-UVB tended to be maintained.
CONCLUSIONS
In the treatment of nonsegmental vitiligo, NB-UVB therapy is superior to oral PUVA therapy.

Read Full Article

 

 

 

 

 


Clinical UVA/UVB PhototherapyFoldalite®-32 - Houva II® - Houva III® - Hand/Foot IITM - TRU-BLU®
Phototherapy for home use: Panosol II® - Dermalight80® - Foldalite III® - DermaLume 2XTM